ALLO vs. CRBU

Last updated Apr 1, 2026

Compare and contrast key facts about Allogene Therapeutics, Inc. (ALLO) and Caribou Biosciences, Inc. (CRBU).

Performance

ALLO vs. CRBU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Allogene Therapeutics, Inc. (ALLO) and Caribou Biosciences, Inc. (CRBU). The values are adjusted to include any dividend payments, if applicable.

ALLO vs. CRBU - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
ALLO Allogene Therapeutics, Inc.	78.10%	-35.68%	-33.64%	-48.97%	-57.84%	-32.34%
CRBU Caribou Biosciences, Inc.	19.50%	0.00%	-72.25%	-8.76%	-58.38%	-7.54%

Fundamentals

Market Cap ALLO : $538.32M CRBU : $179.62M
EPS ALLO : -$0.87 CRBU : -$1.58
PB Ratio ALLO : 1.84 CRBU : 1.47
Total Revenue (TTM) ALLO : $0.00 CRBU : $11.16M
Gross Profit (TTM) ALLO : $0.00 CRBU : $9.85M
EBITDA (TTM) ALLO : -$209.32M CRBU : -$130.70M

Returns By Period

In the year-to-date period, ALLO achieves a 78.10% return, which is significantly higher than CRBU's 19.50% return.

ALLO

• 1D: 9.91%
• 1M: -12.23%
• YTD: 78.10%
• 6M: 96.77%
• 1Y: 67.12%
• 3Y*: -20.95%
• 5Y*: -41.27%
• 10Y*: —

CRBU

• 1D: 10.47%
• 1M: -0.00%
• YTD: 19.50%
• 6M: -18.45%
• 1Y: 108.08%
• 3Y*: -29.01%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ALLO vs. CRBU — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ALLO

ALLO Risk / Return Rank: 67
ALLO Sharpe Ratio Rank: 68
ALLO Sortino Ratio Rank: 70
ALLO Omega Ratio Rank: 66
ALLO Calmar Ratio Rank: 68
ALLO Martin Ratio Rank: 64

CRBU

CRBU Risk / Return Rank: 76
CRBU Sharpe Ratio Rank: 79
CRBU Sortino Ratio Rank: 79
CRBU Omega Ratio Rank: 72
CRBU Calmar Ratio Rank: 78
CRBU Martin Ratio Rank: 72

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ALLO vs. CRBU - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Allogene Therapeutics, Inc. (ALLO) and Caribou Biosciences, Inc. (CRBU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ALLO	CRBU	Difference
Sharpe ratio Return per unit of total volatility	0.77	1.21	-0.44
Sortino ratio Return per unit of downside risk	1.60	2.04	-0.45
Omega ratio Gain probability vs. loss probability	1.19	1.23	-0.03
Calmar ratio Return relative to maximum drawdown	1.31	2.00	-0.70
Martin ratio Return relative to average drawdown	2.47	3.81	-1.34
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ALLO vs. CRBU - Sharpe Ratio Comparison

The current ALLO Sharpe Ratio is 0.77, which is lower than the CRBU Sharpe Ratio of 1.21. The chart below compares the historical Sharpe Ratios of ALLO and CRBU, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ALLO	CRBU	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.77	1.21	-0.44
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.49	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.35	-0.42	+0.08

Correlation

The correlation between ALLO and CRBU is 0.52, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

ALLO vs. CRBU - Dividend Comparison

Neither ALLO nor CRBU has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ALLO vs. CRBU - Drawdown Comparison

The maximum ALLO drawdown since its inception was -98.24%, roughly equal to the maximum CRBU drawdown of -97.58%. Use the drawdown chart below to compare losses from any high point for ALLO and CRBU.

Drawdown Indicators

	ALLO	CRBU	Difference
Max Drawdown Largest peak-to-trough decline	-98.24%	-97.58%	-0.66%
Max Drawdown (1Y) Largest decline over 1 year	-43.95%	-51.06%	+7.11%
Max Drawdown (5Y) Largest decline over 5 years	-97.34%	—	—
Current Drawdown Current decline from peak	-95.48%	-93.73%	-1.75%
Average Drawdown Average peak-to-trough decline	-65.14%	-78.75%	+13.61%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.23%	26.87%	-3.64%

Volatility

ALLO vs. CRBU - Volatility Comparison

Allogene Therapeutics, Inc. (ALLO) has a higher volatility of 32.04% compared to Caribou Biosciences, Inc. (CRBU) at 21.49%. This indicates that ALLO's price experiences larger fluctuations and is considered to be riskier than CRBU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ALLO	CRBU	Difference
Volatility (1M) Calculated over the trailing 1-month period	32.04%	21.49%	+10.55%
Volatility (6M) Calculated over the trailing 6-month period	66.68%	54.48%	+12.20%
Volatility (1Y) Calculated over the trailing 1-year period	88.01%	90.17%	-2.16%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	84.38%	87.52%	-3.14%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.62%	87.52%	-9.90%

Financials